The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy

Abstract

PurposeWe previously demonstrated that the median survival of patients with poor prognosis non–small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was <4 months. We evaluated whether VeriStrat could be used as a prognostic or predictive biomarker in this population.Experimental designWe conducted a randomised double-blind trial among patients with untreated advanced NSCLC considered unfit for platinum chemotherapy because of poor performance status (PS) or multiple comorbidities. All patients received active supportive care (ASC) and were treated with either oral erlotinib or placebo daily. Five hundred twenty-seven patients had plasma samples for VeriStrat classification: good (VeriStrat Good [VSG]) or poor (VeriStrat Poor [VSP]). Main end-point was overall survival.ResultsFifty-five percent patients had VSG, and 83% had Eastern Cooperative Oncology Group (ECOG) 2–3 at baseline. VeriStrat was strongly associated with survival. Among patients managed with ASC only, the adjusted hazard ratio (HR) was 0.54 (p < 0.001) for VSG versus VSP. The association was consistent across patient factors: HR = 0.25 (p = 0.004) and HR = 0.56 (p < 0.001) for ECOG 0–1 and 2–3, respectively, HR = 0.49 (0070 < 0.001) for age≥75 years and HR = 0.59 (p = 0.007) for stage IV. Several ECOG 2–3 patients had long survival: 2-year survival was 8% for VSG patients who had ASC, compared with 0% for VSP. VeriStrat status did not predict benefit from erlotinib treatment because the HRs for erlotinib versus placebo were similar between VSG and VSP patients.ConclusionsVeriStrat was not a predictive marker for survival when considering first-line erlotinib for patients with NSCLC who had poor PS and were not recommended for platinum doublet therapies. However, VeriStrat was an independent prognostic marker of survival. It represents an objective measurement that could be considered alongside other patient factors to provide a more refined assessment of prognosis for this particular patient group. VSG patients could be selected for treatment trials because of better survival, while VSP patients can continue to be treated conservatively or offered trials of less toxic agents.Trial registration ISRCTN NumberISRCTN02370070.

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

“…Other systemic inflammation-based prognostic scores have been proposed to improve the selection of patients to candidate to an appropriate therapy or to direct the treatment allocation and the design of randomized clinical trial. In particular, SAA is also included in the acute phase proteins analyzed by the VeriStrat test (Biodesix, USA), a blood-based proteomic assay which assigns patients to either “good” or “poor” status, and was tested as strong independent indicator of prognosis only for tyrosine kinases inhibitors treatment and chemotherapy, while its value for treatment with ICIs remains unknown [ 30 ].…”

Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis

“…In the smoker group, 2 studies suggest that the PFS and OS of patients in the EGFR-TKI treatment have a trend of being better than those in the placebo group, whereas the study by Lee 2019 was the opposite. [15][16][17] (2) In the 4 studies comparing the efficacy of EGFR-TKIs with chemotherapy, there was no significant difference in improving OS between smokers and nonsmokers NSCLC patients treated with EGFR-TKIs compared with chemotherapy. However, after treatment with EGFR-TKIs, PFS in the non-smoker group was significantly better than the chemotherapy group.…”

Clinical value of CTLA4-associated microRNAs combined with inflammatory factors in the diagnosis of non-small cell lung cancer

“…The reason for the poor prognosis of patients with NSCLC is largely due to the fact that about 75% of NSCLC patients are in advanced stage of cancer at the time of diagnosis, resulting in poor efficacy of various treatments. 13 Therefore, early detection and diagnosis of NSCLC is a key way to improve the prognosis of patients and improve survival rate. The commonly used examination methods for the diagnosis of NSCLC are X-ray examination, bronchoscopy and cytology, but the sensitivity of X-ray examination for NSCLC is only about 45%–50%, and the sensitivity of other methods is also unsatisfactory, especially the detection of patients with early NSCLC.…”